AI Medication Adherence Specialist Interview Questions

Should discuss patient outcomes, healthcare costs, and systemic burden with specific examples.

Should go beyond 'forgot' to include complexity, side effects, cost, or lack of belief in treatment.

Should contrast EHR fields (structured) with clinical notes or patient messages (unstructured).

Should mention legal (HIPAA/GDPR), ethical, and trust aspects.

Should explain it as a model that processes, understands, and generates human language.

Should discuss feature engineering from EHR/claims data (past refills, comorbidities), model selection (classification), and validation strategy.

Should mention prompt engineering, few-shot learning with empathetic examples, or incorporating sentiment analysis to adjust tone.

Should define drift as changes in underlying data patterns over time (e.g., new drug, pandemic behavior) and mention monitoring key metrics like model accuracy or feature distributions.

Should discuss the need for human-in-the-loop, data verification, and designing systems that avoid confrontation, focusing on support.

Should explain FHIR as a standard for exchanging healthcare data (like MedicationRequest) and its role in integrating AI tools with EHR systems.

Should cover a multi-channel orchestration layer, LLM for response generation, separate models for text/voice understanding, a patient state manager, and secure backend with EHR integration.

Should discuss defining protected attributes, calculating fairness metrics (equalized odds, demographic parity), and mitigation techniques like re-sampling or adversarial debiasing.

Should frame it as a contextual bandit problem, where the context is patient state, and the action is the intervention, with the reward being improved adherence. Mention challenges of defining rewards and delayed effects.

Should discuss API vs. self-hosted models, caching common responses, implementing safety classifiers/guardrails, and monitoring for hallucinations or harmful advice.

Should discuss trade-offs, using explainable AI techniques (SHAP, LIME) on complex models, or employing simpler, inherently interpretable models where critical.

Should start with data segmentation, then investigate potential causes: NLP model performance on other languages, cultural appropriateness of interventions, or lack of translated resources.

Should discuss patient consent, data use agreements, purpose limitation, potential for exploitation, and the need to prioritize patient benefit over commercial value.

Should point to data integration lag or ETL pipeline failure, not the model. Immediate fix involves a system-wide safety rule to pause reminders upon adverse event flags.

Should offer to provide a clinician-facing explanation (e.g., 'Patient flagged due to 3 missed refills and recent note of dizziness'), involve them in iterative feedback on feature importance, and propose a trial period.

Should discuss data distribution shift (covariate shift), differences in patient demographics, medication regimens, or healthcare system behaviors not captured in training data.

Should cover: Data validation & versioning, retraining trigger (schedule/performance decay), model training, evaluation against holdout set, shadow deployment, A/B testing, and canary rollout with monitoring.

Should describe a chain: 1) A tool/function to call the FHIR API, 2) A prompt template that takes the medication list as context, 3) An LLM call to generate the message, possibly with a guardrail for tone.

Should involve: Speech-to-text (if not done), NLP pipeline with named entity recognition for symptoms, sentiment analysis for severity, classification into standard terminologies (MedDRA), and a review queue for edge cases.

Should include both system metrics (API latency, error rate) and clinical/business metrics (patient engagement rate, adherence lift, model confidence scores, human intervention rate).

Should describe a confidence threshold; below it, the response is queued for a pharmacist review before being sent. Detail the UI for the pharmacist and the feedback loop to retrain the model.

Should describe collecting implicit and explicit feedback (patient responses, clinician overrides), labeling it, and using it to fine-tune models in a virtuous cycle, while monitoring for bias amplification.

Should reveal communication skills, use of analogy, and focus on practical implications for their domain.

Should demonstrate principled thinking, consultation with guidelines/colleagues, and a decision that prioritized user welfare and transparency.

Should mention specific sources (journals like JAMIA, conferences like NeurIPS Health, regulatory agency newsletters), communities, and time dedicated to continuous learning.

Should show advocacy backed by user research, data, or ethical frameworks, and a collaborative approach to finding a solution.

Should show empathy for different goals, data-driven facilitation, and a focus on the shared ultimate goal of improving patient outcomes.